DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Ulcerative Colitis – Current Treatment – Current Treatment: Physician Insights – Ulcerative Colitis (EU5)
Many well-established therapies are available to treat ulcerative colitis (UC) in the EU5. TNF-alpha (J&J Innovative Medicine’s Remicade and AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Ulcerative Colitis – Geographic Focus: China – Ulcerative Colitis – China In-Depth (China)
Ulcerative colitis (UC) is a chronic, progressive inflammatory bowel disease marked by inflammation and ulceration of the colon and rectum. The primary objective of UC pharmacotherapy is to induce…